Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)

This study has been completed.
Sponsor:
Collaborator:
Genzyme, a Sanofi Company
Information provided by (Responsible Party):
Dr. Sigrun Hallmeyer, Oncology Specialists, S.C.
ClinicalTrials.gov Identifier:
NCT00156013
First received: September 8, 2005
Last updated: June 19, 2014
Last verified: June 2014

September 8, 2005
June 19, 2014
September 2005
April 2010   (final data collection date for primary outcome measure)
  • Phase I Maximum Tolerated Dose [ Time Frame: days 1 -28, maximum 6 cycles ] [ Designated as safety issue: Yes ]
    Maximum Tolerated Dose for ClofaraCohorts of 3 patients each will receive doses of clofarabine increased in increments as follows: 4, 6, 8, 10, 12,…etc mg/m2/day for 5 days. The dose level immediately below the MTD will be used to treat patients in the Phase II part of the study.bine. Starting dose of 4 mg/m2.
  • Phase II Overall Response [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Phase I maximum tolerated dose
  • Phase II overall response
Complete list of historical versions of study NCT00156013 on ClinicalTrials.gov Archive Site
  • Time to Treatment Failure [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Toxicity [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
  • Time to treatment failure
  • Toxicity
Not Provided
Not Provided
 
Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)
A Phase I/II Open-label Study of Clofarabine in Patients With Relapsed or Refractory Diffuse Large Cell B-Cell NHL

This research is being done to develop new treatment for non-hodgkin's lymphoma in subjects whose cancer has returned or resisted treatment with chemotherapy. The investigational drug clofarabine is being used in this study. An investigational drug is one that has not been approved by the United States Food and Drug Administration (FDA).

The safety profile of clofarabine appears acceptable within the target populations studied to date in the clinical studies, with numerous responses observed in heavily pre-treated patients with relapsed/refractory ALL or AML. Dose escalation of clofarabine in patients with solid tumors and lymphoproliferative disorders has been limited because grade 3 and 4 myelosuppression was considered acceptable in patients with acute leukemia, provided that hematologic recovery occurred within 6 weeks of therapy , and dose escalation has proceeded as high as 40 mg/m2 in this patient population. Furthermore, no responses were observed in a recent trial in which patients with relapsed CLL were treated with clofarabine 2 mg/m2, an indolent B-cell lymphoproliferative disorder indicating that low doses are likely to be ineffective in patients with aggressive NHL. (Personal Communication with ILEX Products, INC.)

This Phase I/II study will evaluate escalating doses of clofarabine in patients with relapsed and refractory diffuse large cell B-cell NHL starting at a dose of 4 mg/m2/day for 5 consecutive days and repeated every 28 days for a maximum of 6 cycles. This dosing regimen should be evaluated in this patient population because there is no standard therapy at relapse and grade 3 and 4 myelosuppression is frequently observed with traditional NHL salvage. Additionally, patients will receive granulocyte colony stimulating factors at the discretion of the investigator. Antifungal and antibacterial prophylaxis will be administered to minimize the risk of infection.

Interventional
Phase 1
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Lymphoma, B-Cell
  • Lymphoma, Non-Hodgkin
Drug: CLOFARABINE
4 mg/m^2 days 1-5 of every cycle for a maximum of 6 cycles
Other Name: Clolar®
Experimental: 1
Clofarabine 4 mg/m^2 days 1-5 of every cycle for a maximum of 6 cycles.
Intervention: Drug: CLOFARABINE
Nabhan C, Davis N, Bitran JD, Galvez A, Fried W, Tolzien K, Foss S, Dewey WM, Venugopal P. Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients. Cancer. 2011 Apr 1;117(7):1490-7. doi: 10.1002/cncr.25603. Epub 2010 Nov 8.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
33
April 2010
April 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult patients who are at least 18 years old with histology confirmed diffuse large cell B-cell NHL who have failed prior systemic chemotherapy with or without monoclonal antibody-based therapies.
  • Measurable disease determined by Ct or PET scans or bone marrow involvement, defined as lesions that can be accurately measured in two dimensions by CT or PET scan with the longest diameter accurately as greater than or equal to 1.0 cm or palpable lesions with both diameters greater than or equal to 2.0 cm. PET scan measurable disease is defined based on SUV value as determined by nuclear medicine evaluation.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0,1,or 2.
  • Life expectancy greater than 12 weeks.
  • Laboratory values obtained less than or equal to 14 days prior to registration:

    • Absolute neutrophil count (ANC) greater than or equal to 1500.
    • White blood cell (WBC) count greater than 3.0.
    • Platelets greater than or equal to 100.
    • Hemoglobin (HG) greater than 9.0 g/dL.
    • Total bilirubin less than or equal to 2.0 mg/dL.
    • Aspartate transaminase (AST)/alanine transaminase (ALT) less than or equal to 3 times the upper limit of normal (ULN). Higher values are acceptable if it is deemed that they are related to liver involvement with NHL.
    • Serum creatinine less than or equal to 2.0 mg/dL.
  • Cardiac function on pretreatment MUGA scan or echocardiogram that is considered normal by institutional standards.
  • Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent.
  • Female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment.
  • Male and female patients must use an effective contraceptive method during the study and for a minium of 6 months after study treatment.

Exclusion Criteria:

  • Previously untreated NHL.
  • Received previous treatment with clofarabine.
  • History of T-cell lymphoma.
  • Bulky disease (ie, any single mass greater than 10 cm or circulating malignant cells greater than or equal to 24,000 cells/ul.
  • Patients with known AIDS-related or HIV-positive lymphoma.
  • Autologous bone marrow or stem cell transplant within 3 months of study entry.
  • History of allogeneic bone marrow transplant or organ transplant.
  • Prior radiotherapy to the only site of measurable disease.
  • Any medical condition that requires chronic use of oral high-dose corticosteroids. ( in excess of 1 mg/kg/day).
  • Autoimmune thrombocytopenia.
  • Use if investigational agents within 30 days or any anticancer therapy within 3 weeks before study entry. The patient must have recovered from all acute toxicities from any previous therapy.
  • Patients with an active, uncontrolled systemic infection considered to be opportunistic, life threatening, or clinically significant at the time of treatment or with a known or suspected fungal infection (ie, patients of parenteral antifungal therapy).
  • HIV-positive status.
  • Active secondary malignancy.
  • Pregnant or lactating patients.
  • Any significant concurrent disease, illness , or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow-up, or interpretation of study results.
  • Patients with active or untreated central nervous lymphoma (CNS) lymphoma.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00156013
1066306 (0408)
No
Dr. Sigrun Hallmeyer, Oncology Specialists, S.C.
Oncology Specialists, S.C.
Genzyme, a Sanofi Company
Principal Investigator: Chadi Nabhan, MD Oncology Specialists,SC
Oncology Specialists, S.C.
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP